Takeda discontinuation of GAMMAGARD® S/D
October 22, 2026
This is a courtesy notification to remind you of Takeda's planned discontinuation of GAMMAGARD S/D by the end of 2027.
Previously announced by Takeda in June 2025, the discontinuation is not related to a product quality issue; its safety and efficacy remain consistent with the product Prescribing Information. Takeda states: "As the only lyophilized (freeze-dried) preparation in Takeda's IG portfolio, GAMMAGARD S/D uses a different, older manufacturing process. This decision is based on the need to move beyond older production methods that are no longer sufficient to meet long-term patient needs."
Supply is expected to gradually decrease through December 2027 as production volumes decline. Limited inventory may remain available beyond that date until inventory is depleted or expires.
Takeda is encouraging healthcare teams to transition appropriate patients to alternative therapies for continuity of care.
Please utilize, if needed, the communication resources from Takeda below:
Let Us Help
If you have further questions or would like to order alternative therapies, please reach out to our friendly Wow! Customer Care team at (800) 843-7477 or your FFF Sales Representative. We're here for you!
